Most Recent Articles by C. Andrew Kistler, MD, PharmD, RPh
Gastrinomas, rare endocrine tumors, can be treated in multiple ways, regardless of whether the tumor is resectable.
A number of studies have attempted to determine whether multiple myeloma is directly linked to autoimmune disease.
New and old biomarkers should be included in clinical trials to help build a database from which oncologists can draw sound clinical recommendations.
If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit analysis before deciding whether to continue treatment.
Rarely, patients with prostate cancer will develop metastases to the gastrointestinal tract, which limit treatment options.
More Articles by C. Andrew Kistler, MD, PharmD, RPh
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|